These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35908505)

  • 1. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents.
    Theofilis P; Sagris M; Oikonomou E; Antonopoulos AS; Siasos G; Tsioufis K; Tousoulis D
    Int Immunopharmacol; 2022 Oct; 111():109080. PubMed ID: 35908505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
    Buttice L; Ghani M; Suthakar J; Gnanalingham S; Carande E; Kennedy BWC; Pitcher A; Gamble JHP; Ahmad M; Lewis A; Jüni P; Rider OJ; Stephens JW; Bray JJH
    Diabetes Obes Metab; 2024 Jul; 26(7):2706-2721. PubMed ID: 38602398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials.
    Gohari S; Ismail-Beigi F; Mahjani M; Ghobadi S; Jafari A; Ahangar H; Gohari S
    BMC Endocr Disord; 2023 Nov; 23(1):257. PubMed ID: 37996879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can coenzyme Q10 supplementation effectively reduce human tumor necrosis factor-α and interleukin-6 levels in chronic inflammatory diseases? A systematic review and meta-analysis of randomized controlled trials.
    Farsi F; Heshmati J; Keshtkar A; Irandoost P; Alamdari NM; Akbari A; Janani L; Morshedzadeh N; Vafa M
    Pharmacol Res; 2019 Oct; 148():104290. PubMed ID: 31185284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder.
    Nakhal MM; Aburuz S; Sadek B; Akour A
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials.
    Tabrizi R; Tamtaji OR; Mirhosseini N; Lankarani KB; Akbari M; Dadgostar E; Borhani-Haghighi A; Peymani P; Ahmadizar F; Asemi Z
    Pharmacol Res; 2019 Mar; 141():85-103. PubMed ID: 30576798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia.
    Heimke M; Lenz F; Rickert U; Lucius R; Cossais F
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
    Sayour AA; Celeng C; Oláh A; Ruppert M; Merkely B; Radovits T
    Diabetologia; 2021 Apr; 64(4):737-748. PubMed ID: 33483761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis.
    Theofilis P; Antonopoulos AS; Katsimichas T; Oikonomou E; Siasos G; Aggeli C; Tsioufis K; Tousoulis D
    Pharmacol Res; 2022 Jun; 180():106243. PubMed ID: 35523389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.
    Mashayekhi M; Safa BI; Gonzalez MSC; Kim SF; Echouffo-Tcheugui JB
    Trends Endocrinol Metab; 2024 May; 35(5):425-438. PubMed ID: 38423898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials.
    Wang D; Liu J; Zhong L; Li S; Zhou L; Zhang Q; Li M; Xiao X
    Front Pharmacol; 2022; 13():1045235. PubMed ID: 36467062
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
    Mazidi M; Rezaie P; Gao HK; Kengne AP
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis.
    Liu C; Feng X; Li Q; Wang Y; Li Q; Hua M
    Cytokine; 2016 Oct; 86():100-109. PubMed ID: 27498215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.
    Bonnet F; Scheen AJ
    Diabetes Metab; 2018 Dec; 44(6):457-464. PubMed ID: 30266577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Feng C; Wu M; Chen Z; Yu X; Nie Z; Zhao Y; Bao B
    Int Urol Nephrol; 2019 Apr; 51(4):655-669. PubMed ID: 30830656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of inflammatory biomarkers associated with malaria infection and disease severity.
    Hashmi F; Aqeel S; Zuberi UF; Khan W
    Cytokine; 2023 Sep; 169():156305. PubMed ID: 37482049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.